TSC RESEARCH, LLC v. Bayer Chemicals Corp.

552 F. Supp. 2d 534, 2008 U.S. Dist. LEXIS 38171, 2008 WL 2001976
CourtDistrict Court, M.D. North Carolina
DecidedMarch 4, 2008
Docket1:06-m-00069
StatusPublished
Cited by28 cases

This text of 552 F. Supp. 2d 534 (TSC RESEARCH, LLC v. Bayer Chemicals Corp.) is published on Counsel Stack Legal Research, covering District Court, M.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
TSC RESEARCH, LLC v. Bayer Chemicals Corp., 552 F. Supp. 2d 534, 2008 U.S. Dist. LEXIS 38171, 2008 WL 2001976 (M.D.N.C. 2008).

Opinion

ORDER

WILLIAM L. OSTEEN JR., District Judge.

On November 29, 2007, the United States Magistrate Judge’s Recommendation was filed and notice was served on the parties pursuant to 28 U.S.C. § 636. No objections were filed within the time limits prescribed by Section 636.

Therefore, the court need not make a de novo review and the Magistrate Judge’s Recommendation is hereby adopted.

IT IS THEREFORE ORDERED that, as a result of both the decisions set out in the Recommendation and those made in the hearing, Defendant’s motion to dismiss (Doc. No. 21) is granted as to Counts 7, 8, 9, 10, 11, 12, and 13 of the amended complaint and denied as to Counts 3 and 6.

IT IS FURTHER ORDERED that the contract claims in Counts 2, 4, and 5 are dismissed for being substantively subsumed and incorporated in Count 3.

ORDER AND RECOMMENDATION OF MAGISTRATE JUDGE ELIASON

RUSSELL A. ELIASON, United States Magistrate Judge.

This case is before the Court on Defendants’ motion to dismiss Plaintiffs amended complaint pursuant to Fed.R.Civ.P. 12(b)(6). The Court held a hearing on the present motion on March 22, 2007, in which it orally dismissed Counts 2, 4, 5, and 13 of Plaintiffs thirteen-count amended complaint. 1 The Court also gave Plain *537 tiff 45 days to file a more definite statement as to Counts 9, 10, and 12 of the complaint and 30 days to rebrief Counts 6, 7, and 8. {See Docket No. 33.) The further statements, briefing, and responses of the parties are now before the Court.

The facts, in the light most favorable to Plaintiff, are as follows. In early 2003, Plaintiff TSC Research, LLC met with Defendant Bayer Chemicals Corporation (“Bayer”) regarding a chemical-based technology developed by Plaintiff. The technology involved the manufacturing of “smart fabrics,” which could improve temperature and moisture control for the wearer. The two parties executed a Disclosure Agreement in April 2003, whereby Plaintiff provided enough proprietary information to allow Defendant Bayer to manufacture the requisite chemicals to create “smart fabrics.” Shortly thereafter, Plaintiff claims that Defendant Bayer expressed its desire to manufacture and market the technology as a Bayer product, and the two companies executed a “Letter of Intent to Execute the Exclusive Technology Licensing Agreement” (hereinafter “the letter of intent”) on October 22, 2003. Bayer’s marketing director, Dean Bender (“Bender”), signed the agreement on behalf of Defendant.

The letter of intent explained that the parties desired to execute an attached licensing agreement “pending any necessary final approvals,” (emphasis added), and that the parties signed the letter of intent in “good faith.” It also contained assurances by Defendant Bayer that it would expedite the approval of the licensing agreement, and that the two parties would proceed as if that agreement had already been approved. Accordingly, the parties met on several occasions to discuss Plaintiffs technology, including during a number of meetings with Defendant’s customers. (Compl. ¶ 32-36.) During this time, Defendant Bayer paid Plaintiff $30,000 per month as set forth in the unex-ecuted licensing agreement.

After several uneventful months, events took an ábrupt turn when Defendant Bayer decided to reorganize its corporate structure in early 2004. At that time, it transferred its chemical division to a new entity, LANXESS Corporation (“LANX-ESS”), which is also a named defendant in this action. Plaintiff claims that Bender’s resignation from Bayer in March 2004, in the midst of the reorganization, led to even greater confusion over the future of the companies’ joint enterprise. It particularly alleges that the new LANXESS officials showed little to no interest in Plaintiffs technology and allowed “the venture between plaintiff TSC and defendant Bayer to ‘die on the vine.’ ” (Compl. ¶ 45.) Despite these changes, the parties “continued discussions and held meetings” regarding Plaintiffs technology as late as June 2004. (Compl. ¶ 39.)

Between July and September of 2004, the parties proceeded with their communications regarding the proposed 15-year licensing agreement. Defendants’ legal department allegedly sought “additional *538 assurances and information” from Plaintiff during this period, but neither Bayer nor LANXESS made any further payments to Plaintiff. Meanwhile, Plaintiff claims that Defendants “failed to respond or to provide accurate and timely updates as to the status regarding the execution of the license agreement or the continued pursuit of customers for the TSC Process.” (Compl. ¶ 42.) Plaintiff also asserts that its ultimate decision to file suit against Defendants on February 22, 2005 came only after “23 face-to-face meetings” between the parties proved unsuccessful. (Compl. ¶ 53.) Nonetheless, Plaintiff and Defendant LANXESS entered a one-year tolling agreement on March 14, 2005 in a further attempt to reach an agreement as to the licensing of Plaintiffs product. However, even after the parties extended the tolling agreement for four additional months, they failed to reach an agreement. Plaintiff claims that Defendants did little, if anything, to advance the future relationship between the companies during the tolling period. On August 22, 2006, soon after tolling expired, Defendants removed this action to federal court on diversity of citizenship grounds. They now seek to dismiss all remaining counts of Plaintiffs amended complaint for failure to state a claim under Fed.R.Civ.P. Rule 12(b)(6).

Discussion

To survive a motion to dismiss pursuant to Fed.R.Civ.P. 12(b)(6), a plaintiff must first comply with Fed.R.Civ.P. 8(a)(2), which requires “ ‘a short and plain statement of the claim showing that the pleader is entitled to relief,’ in order to ‘give the defendant fair notice of what the ... claim is and the grounds upon which it rests.’ ” Bell Atlantic Corp. v. Twombly, — U.S. -, 127 S.Ct. 1955, 1964, 167 L.Ed.2d 929 (2007)(quoting Conley v. Gibson, 355 U.S. 41, 47, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957)).

While a complaint attacked by a Rule 12(b)(6) motion to dismiss does not need detailed factual allegations, a plaintiffs obligation to provide the “grounds” of his “entitle[ment] to relief’ requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do. Factual allegations must be enough to raise a right to relief above the speculative level on the assumption that all the allegations in the complaint are true.

Twombly, 127 S.Ct. at 1964-65 (internal citations omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
W.D. North Carolina, 2026
CHASE CORPORATION v. QUINT BAREFOOT
M.D. North Carolina, 2025
BEATTY v. PRUITTHEALTH INC.
M.D. North Carolina, 2024
Robert Greer v. Strange Honey Farm
114 F.4th 605 (Sixth Circuit, 2024)
Three Reasons, LLC v. JAB-C, LLC
W.D. North Carolina, 2024
COLE v. MONTGOMERY
M.D. North Carolina, 2023
Greer v. Hagen
E.D. Tennessee, 2023
Taylor v. Manis
W.D. Virginia, 2021
MACREGEN, INC. v. BURNETTE
M.D. North Carolina, 2021
WILLIAMS v. WILLIAMS
M.D. North Carolina, 2021
GUHNE v. CERIDIAN HCM, INC.
M.D. North Carolina, 2021
LINDEMANN-MOSES v. JACKMON
M.D. North Carolina, 2020

Cite This Page — Counsel Stack

Bluebook (online)
552 F. Supp. 2d 534, 2008 U.S. Dist. LEXIS 38171, 2008 WL 2001976, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tsc-research-llc-v-bayer-chemicals-corp-ncmd-2008.